MA
CRVS icon

MYDA Advisors’s Corvus Pharmaceuticals CRVS Stock Holding History

MYDA Advisors’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-71,011
Closed -$125K – 127
2023
Q4 		$125K Buy
71,011
+2,197
+3% +$3.21K 0.04% 81
2023
Q3 		$100K Sell
68,814
-31,186
-31% -$66K 0.03% 98
2023
Q2 		$229K Buy
+100,000
New +$208K 0.07% 98
2021
Q4 		– Sell
-60,000
Closed -$290K – 273
2021
Q3 		$290K Buy
+60,000
New +$178K 0.08% 197

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
SC
Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TL
TowerView LLC New York $152M AUM 20.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

MYDA Advisors's CRVS Position: Q1 2024 in Review

MYDA Advisors sold out of Corvus Pharmaceuticals (CRVS) in Q1 2024, closing a stake of 71,011 shares — an estimated $125K sold.

MYDA Advisors first reported a position in CRVS in Q3 2021 and held it in 4 quarters. The position peaked at $290K in Q3 2021. 47 funds tracked by Wall St. Rank hold CRVS as of Q1 2024.

  • MYDA Advisors reported no remaining Corvus Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • MYDA Advisors sold 71,011 Corvus Pharmaceuticals shares in Q1 2024, an estimated $125K.
  • MYDA Advisors first reported a position in Corvus Pharmaceuticals in Q3 2021 and held it in 4 quarters.
  • MYDA Advisors's Corvus Pharmaceuticals position peaked at $290K in Q3 2021.
  • 47 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2024.

Based on MYDA Advisors's 13F filing for Q1 2024, filed 14 May 2024.